Advanced Hepatocellular Carcinoma in A Scottish Population – Current Experience and the Future by Baxter MA in Current Trends in Gastroenterology and Hepatology in Lupine Publishers
Sorafenib is the current first line standard of care in patients with advanced hepatocellular carcinoma (HCC). Several other
drugs are emerging as efficacious agents in this setting. This article will outline our current real-world experience with sorafenib in
a Scottish population as well as discuss the evidence behind new potential therapies.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.